Anti-TRA-1-60 [Bstrongomab-9A] Antibody

This is a purified mouse IgG1 monoclonal antibody was generated against purified stem cell marker TRA-1-60 antigen from the human embryonal carcinoma Tera-1.

Highlights:

  • Only commercially available IgG format TRA-1-60 antibody
  • High specificity and reactivity to the TRA-1-60 carbohydrate antigen, a cell surface marker for all human pluripotent embryonic stem cells
  • Suitable for Western Blot, Immunohistochemistry/ImmunoFluorescence, Immunoprecipitation, and Flow cytometry applications

TRA-1-60 is a pluripotent specific carbohydrate molecule present on the cell adhesion protein Podocalyxin. TRA-1-60 is highly expressed on normal embryonic stem cells. For the past forty years It has been used as the gold standard cell surface marker for all normal human embryonic stem cells. TRA-1-60 expression is lost upon differentiation of stem cells and is not present on normal differentiated human cells. Recently, numerous published studies have shown that TRA-1-60 is re-expressed in many kinds of human cancers: TRA-1-60 may be a cell marker of cancer cells with stem cell properties.

From the laboratory at CureMeta.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
FCM001
Anti-TRA-1-60 [Bstrongomab-9A] Antibody
100ug In stock
Regular Price:$250.00
On Sale:
Specifications

Product Type: Antibody
Accession ID: PODXL podocalyxin like [Homo sapiens (human)] Gene ID: 5420
Antigen: TRA-1-60, Podocalyxin, gp200, GCTM-2, PCLP-1
Molecular Weight: 200-240 kDa
Isotype: IgG1
Clonality: Monoclonal
Clone Name: Bstrongomab-9A
Reactivity: TRA-1-60
Specificity: Human
Immunogen: Carbohydrate
Species Immunized: Mouse
Epitope: Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc
Purification Method: Protein A
Method Used to Determine Concentration: OD280
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2-7.4
Tested Applications: Western Blotting (1:1000 with 1mg/ml), Immunohistochemistry/ImmunoFluorescence (1:200 with 1mg/ml), Immunoprecipitation, Flow cytometry
Concentration: 1 mg/mL
Storage: Store at 4C short term. For long term storage, store at -20C. It is recommended that multiple freeze thaw cycles are avoided.
Shipped: Cold packs

Data

 

CureMeta
Comparison of anti-TRA-1-60 antibody Bstrongomab (IgG) against commercially available anti-TRA-1-60 IgM antibody. Western blots of cell membrane protein preps run on 7.5% SDS-PAGE. Control cells with no TRA-1-60 (PC3) and human embryonal carcinoma cell lines with high TRA-1-60 expression (PCSC-1, PCSC-2). Anti-TRA-1-60 IgM antibody used at 1ug/ml and Bstrongomab at 0.5ug/ml dilutions followed with HRP conjugated secondary antibody at 1ug/ml concentration.

 

 

CureMeta
Bstrongomab anti-TRA-1-60 antibody Immunohistochemistry staining shows strong reactivity in many cancers but no staining in normal tissues. Method: The formalin-fixed paraffin-embedded tissues were sectioned at 5um.Sections were deparaffinized, rehydrated in water, and prepared by heat-induced antigen retrieval by Diva Decloaker (Biocare Medical, Cat# DV2004MX) and Decloaking Chamber (Biocare Medical).Sections were stained with Bstrongomab (1mg/ml, 1:500, Curemeta), and Mouse IgG1, k isotype control antibody (1:500, Biolegend, Cat# 401407) by using PowerVision+ poly-HRP IHC detection systems (Leica, Cat# PV6106).

 

Provider
From the laboratory at CureMeta.
References
  1. TRA-1-60-positive/CD45(low) cells found in the peripheral blood of prostate cancer patients with metastatic disease - A proof-of-concept study. Schäfer C, Ju Y, Tak Y, Vazquez C, Han SJ, Tan E, Shay JW, Holmqvist M, Danuser G, Schopperle WM, Bubley G. Heliyon. 2020 Jan 24;6(1):e03263. doi: 10.1016/j.heliyon.2020.e03263. eCollection 2020 Jan.
  2. Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. White JM, Kuda-Wedagedara AN, Wicker MN, Spratt DE, Schopperle WM, Heath E, Viola NT. Mol Pharm. 2020 Apr 6;17(4):1139-1147.

TRA-1-60 in Human Embryonic Stem Cells:

  1. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Badcock G, Pigott C, Goepel J, Andrews PW. Cancer Res. 1999 Sep 15;59(18):4715-9.
  2. The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Schopperle WM, DeWolf WC. Stem Cells. 2007 Mar;25(3):723-30. doi: 10.1634/stemcells.2005-0597. Epub 2006 Nov 22.
  3. The binding specificity of the marker antibodies Tra-1-60 and Tra-1-81 reveals a novel pluripotency-associated type 1 lactosamine epitope. Natunen S, Satomaa T, Pitkänen V, Salo H, Mikkola M, Natunen J, Otonkoski T, Valmu L. Glycobiology. 2011 Sep;21(9):1125-30. doi: 10.1093/glycob/cwq209. Epub 2010 Dec 15.

TRA-1-60 in human cancer:

  1. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer. Lajer H, Daugaard G, Andersson AM, Skakkebaek NE. Int J Cancer. 2002 Jul 10;100(2):244-6. doi: 10.1002/ijc.10459.
  2. Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas. Takata K, Saito K, Maruyama S, Miyata-Takata T, Iioka H, Okuda S, Ling Y, Karube K, Miki Y, Maeda Y, Yoshino T, Steidl C, Kondo E. Cancer Sci. 2019 Jan;110(1):443-457. doi: 10.1111/cas.13870. Epub 2018 Dec 8.
  3. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Nat Commun. 2011 Jan 18;2:162. doi: 10.1038/ncomms1159.
  4. Stem cell markers as predictors of oral cancer invasion. Siu A, Lee C, Dang D, Lee C, Ramos DM. Anticancer Res. 2012 Apr;32(4):1163-6.

If you publish research with this product, please let us know so we can cite your paper.

Loading...